We are live on ! Find out more
CLGN icon

CollPlant Biotechnologies

19 hedge funds and large institutions have $4.08M invested in CollPlant Biotechnologies in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

61% more capital invested

Capital invested by funds: $2.53M → $4.08M (+$1.54M)

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

6% more funds holding

Funds holding: 1819 (+1)

2.86% less ownership

Funds ownership: 14.78%11.92% (-2.9%)

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

Holders
19
Holders Change
+1
Holders Change %
+5.56%
% of All Funds
0%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
5
Reduced
6
Closed
2
Calls
Puts
Net Calls
Net Calls Change

CLGN Hedge Fund Activity: Q3 2025 in Review

19 institutional investors reported a position in CollPlant Biotechnologies (CLGN) for Q3 2025, worth a combined $4.08M — up 61% from $2.53M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new CLGN positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 6 trimmed.

The largest buyer was St. Denis J. Villere & Co, adding an estimated $99.8K. The largest seller was Heights Capital Management, cutting an estimated $610K.

  • 19 institutional investors held CollPlant Biotechnologies (CLGN) as of Q3 2025, up from 18 in Q2 2025.
  • Funds reported $4.08M of CollPlant Biotechnologies stock for Q3 2025, up 61% quarter-over-quarter.
  • 3 funds opened new CollPlant Biotechnologies positions in Q3 2025 and 2 closed out, a net change of +1 holder.
  • The largest CollPlant Biotechnologies buyer in Q3 2025 was St. Denis J. Villere & Co, an estimated $99.8K added.
  • The largest CollPlant Biotechnologies seller in Q3 2025 was Heights Capital Management, an estimated $610K sold.

Based on aggregated 13F filings for Q3 2025.